Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metformin - Anji Pharma

Next Previous
X
Search
Drug Profile

Metformin - Anji Pharma

Alternative Names: ANJ900; EFB0027; Met DR; Metformin delayed release - Anji Pharma; NewMet

Latest Information Update: 23 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elcelyx Therapeutics
  • Developer Anji Pharma; Elcelyx Therapeutics
  • Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 14 Mar 2023 Anji Pharma terminates the phase III DREAM-T2D trial in Type 2 diabetes mellitus in USA (PO) due to strategic company decision - not related to a safety concern (NCT04854512)
  • 02 Jun 2022 Anji Pharmaceuticals plans a pivotal phase III trial for Type 2 diabetes mellitus in U.S, China, and rest of world in the fourth quarter of 2022
  • 28 Feb 2022 Anji Pharma completes a phase I trial in Type 2 diabetes mellitus (In volunteers) in China (PO) (NCT05151146)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top